Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
The agreement covers multiple federal lawsuits involving its Depo-Provera contraceptive and claims of an increased risk of intracranial meningioma, according to a report.
THE APEX TIMES
THE APEX TIMES
Moderna shares rose about 158% in August to lead the S&P 500, according to Yahoo Finance, as Edison International dropped roughly 27% to rank at the bottom of the index.
THE APEX TIMES
A market report said Eli Lilly unveiled a $2.9 billion deal tied to its Merida program, prompting investors to reassess near-term valuation and integration risks.
THE APEX TIMES
A rebound in healthcare equities in the week leading up to Aug. 21 traced back to trading momentum around clinical news tied to Moderna’s work and a Merck cancer study, according to a Yahoo Finance market recap.
THE APEX TIMES
A new market report frames Pfizer’s near-term oncology momentum around Padcev, while pointing to PF-08634404 and potential label expansion efforts as catalysts the company expects to matter later.
THE APEX TIMES
The deal would bring privately held Merida Biosciences into Eli Lilly’s portfolio as the Indianapolis drugmaker pushes further into immune-related and allergic conditions, according to a report published Monday.
THE APEX TIMES
A reported acquisition plan by Eli Lilly adds an early-stage autoimmune platform as the company continues to widen its pipeline, positioning the spending as separate from its obesity push.
THE APEX TIMES
The acquisition, announced as a move in biotech drug development, would expand Eli Lilly’s pipeline through the purchase of Merida Biosciences, with consideration structured as an up-to amount paid in cash.
THE APEX TIMES
Both Pfizer and Starbucks raised their outlooks this summer, but the difference in how aggressive each company’s recovery narrative is can shape investor expectations about durability, cost control, and the timing of cash flow improvements.
